Two injectable therapies accounted for nearly 100 percent of medications for patients in 2001, but by 2020 that decreased to about 25 percent. The majority of individuals with multiple sclerosis (MS) ...

In a landmark regulatory achievement that reflects the UAE’s leadership in accelerating access to innovative therapies, the Emirates Drug Establishment has announced the approval of “Tolebrutinib” as ...

In just a few years, multiple sclerosis patients may have the option of taking an oral medication rather than injections. About 400,000 Americans acknowledge having MS, a condition that affects the ...

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in the EU and ...

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a Phase 3 clinical study titled ...

PARIS--(BUSINESS WIRE)--The French pharmaceutical company, Juvisé Pharmaceuticals, announces the acquisition of global commercial rights (excluding the United States and Canada) to Ponvory® (ponesimod ...

Roche Holdings AG's RHHBY Phase 2 FENopta study of oral fenebrutinib for relapsing forms of multiple sclerosis (RMS) met its primary and secondary endpoints. The data showed oral fenebrutinib ...

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system (CNS), including the brain, spinal cord, and optic nerves. The body mistakenly attacks and damages the protective ...

In the "real world," patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were ...